Result:Weak· Market: Up#Margin expansion#Cost led
| Metric | Value (₹ Cr) | Q1 FY26 |
|---|---|---|
| Revenue | 0.83 | 36.3% |
| Total Income | 0.83 | 36.3% |
| Expenditure | 0.75 | 37.9% |
| PBT | 0.08 | 16.3% |
| Net Profit | 0.08 | 16.3% |
| OPM | 29.39% | 10.13pp |
| NPM | 9.69% | 2.31pp |
| EPS | 0.14 | 36.4% |
Revenue fell 36% YoY and PAT dropped 16% despite margin expansion from cost cuts, indicating core business contraction typical of a weak quarter for this small pharma name.
Informational and educational content only. Not investment advice.